Monitor the company's proxy statement and 10-K for details on the proposed share increase in the stock incentive plan, as this could impact future dilution. The outcome of these votes is expected to be routine with management recommendations likely to pass.
BCRX drugs
BCRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 24 $8.94entry
- T+1 · 7mo ago −0.45%α −0.61% · $8.90
- T+5 · 7mo ago +2.46%α +1.55% · $9.16
- T+20 · 6mo ago −6.38%α −10.40% · $8.37
- T+60 · 4mo ago +5.37%α +0.29% · $9.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioCryst Pharmaceuticals is holding its 2026 annual meeting to vote on several proposals, including the election of three directors, ratification of auditors, an advisory vote on executive compensation, and approval of an amended stock incentive plan to increase shares available for issuance. This is a routine annual shareholder meeting with no activist involvement or contested issues.
Key Financial Metrics
Key Facts
- Annual meeting scheduled for June 11, 2026
- Three director nominees: Theresa M. Heggie, Amy E. McKee, M.D., and Jon P. Stonehouse
- Proposal to ratify Ernst & Young LLP as independent auditors
- Advisory vote on executive compensation
- Proposal to amend and restated Stock Incentive Plan to increase shares available for issuance
Financial Impact
Approval of the amended Stock Incentive Plan would increase dilution potential, but no specific share count or financial impact is disclosed in this filing
Risk Factors
- Potential dilution from approval of additional shares in the stock incentive plan
- Shareholder opposition to executive compensation if deemed excessive
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-016373 |
| Document: 0001140361-26-016373-index-headers.html | 0001140361-26-016373 |
| Document: 0001140361-26-016373-index.html | 0001140361-26-016373 |
| Document: 0001140361-26-016373.txt | 0001140361-26-016373 |
Track record
20 reports on BCRX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
- Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers